Berdagang Vir Biotechnology VIR

VirBiotechnology carta live

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tunjukkan lebih lagi
N/A
Noah Lee 2025 Jul 03, 08:35

Wall Street Strategist: Potential $100B+ Stock Market Influx Coming

N/A
Sophia Claire 2025 Jul 03, 08:35

Euro Surges in Foreign Exchange Options Market Amid Bullish Sentiment

N/A
Emma Rose 2025 Jul 03, 08:35

AI Podcast: The Pennsylvania Plan - Domestic Investors to the Rescue?

N/A
liam james 2025 Jul 03, 08:35

AI Podcast: Dollar Weakens Amid Fed Chair Uncertainty

N/A
liam james 2025 Jul 03, 08:35

JPMorgan Model Predicts Stock Market Upswing: An AI Podcast Breakdown

N/A
Ava Grace 2025 Jul 03, 08:35

Dollar Index Plummets Amid Fed Independence Concerns

N/A
liam james 2025 Jul 03, 07:35

AI Podcast: Decoding Economic Indicators and Fed Policy

N/A
Sophia Claire 2025 Jul 03, 07:35

AI Podcast: S&P 500 Hits Record High, Sparking Market Bubble Fears

Maklumat

Sebaran nilai

0.05

Spread (%)

0.9242 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Khamis

13:31 - 16:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

750632320

Saham Tertunggak

138238000

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-4.23

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tunjukkan lebih lagi
Trustpilot